Gilead Sciences' (GILD) First COVID-19 Antiviral Data Validates Remdesivir - Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Gilead Sciences (NASDAQ: GILD) | Delayed: 170.33 -0.35 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $170.68 | 52 Week High | $108.63 | |||
| Open | $169.85 | 52 Week Low | $71.39 | |||
| Day High | $172.61 | P/E | 94.10 | |||
| Day Low | $166.38 | EPS | $1.81 | |||
| Volume | 8,875,847 | |||||
